The FDA has approved pembrolizumab (Keytruda) combined with platinum-based chemotherapy for the treatment of patients with unresectable, advanced, or metastatic…
Browsing: oncology
The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage…
On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (IMFINZI®, AstraZeneca) in combination with platinum-containing chemotherapy…
AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered…
Genetic Testing Cancer In recent years, the field of oncology has witnessed significant advancements, particularly in the realm of genetic…
Introduction During a comprehensive presentation by Dr. Catherine Coombs at UC Irvine, insights into the unique challenges and opportunities of…
Introduction At a recent conference, Dr. Anjali Advani of the Cleveland Clinic discussed the transformative role of Chimeric Antigen Receptor…
Introduction During the CAR-T & Bispecifics Conference, Dr. Brian Sworder, MD, from UCI Irvine, shared compelling insights on the utility…
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment…
Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series…
Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel…
Can you make optimal treatment choices for challenging triple-negative breast cancer (TNBC) cases? Put your TNBC skills to the test…
With over 55% of cancer patients treated by community oncologists, it’s imperative that community oncologists and pathologists apply a multidisciplinary…
This immersive practice guide offers “how to†methods and day-to-day strategies via faculty commentary and a review of data and…
Are you aware that Black men continue to suffer worse outcomes compared to White men with prostate cancer? Through this…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…